NovoCure Limited

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
10.99 ^USD	-12.29%		+8.38%	-15.00%

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT

Published on 07/27/2023 at 08:00 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Novocure Q2 2023 Earnings Conference Call. [Operator Instructions]. Please be advised that

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT
Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE
Dec. 01	NovoCure Names Frank Leonard as Chief Executive	MT
25-10-30	NovoCure Limited, Q3 2025 Earnings Call, Oct 30, 2025
25-10-30	NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	NovoCure Q3 Net Loss Widens, Revenue Rises	MT
25-10-30	Novocure Q3 revenue beats estimates	RE
25-10-30	Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M	MT
25-10-01	Novocure to report third quarter 2025 financial results	RE
25-09-29	Novocure to present final results from pivotal phase 3 Metis trial of its Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer at 2025 Astro Annual Meeting	RE
25-09-29	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of Its Tumor Treating Fields Therapy for Brain Metastases from Non-Small Cell Lung Cancer At 2025 ASTRO Annual Meeting	CI
25-09-15	Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer	CI
25-09-15	NovoCure's Optune Lua Receives Approval in Japan to Treat Certain Non-Small Cell Lung Cancer Patients	MT